Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Guangzhou, China
Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Guangzhou, China
复制标题
DOI：
10.1111/j.1524-4733.2009.00636.x
复制
发表时间：
2009-11-01
期刊：
影响因子：
4.5
通讯作者：
Chen, Wen
中科院分区：
文献类型：
--
作者：
Hu, Min;Chen, Wen
目的：目的：估算北京和广州地区慢性B肝炎（CHB）相关疾病给每位患者及其家庭带来的年度总经济负担。方法：对CHB相关疾病（CHB、代偿期肝硬化、失代偿期肝硬化和肝癌）的经济负担进行分析。采用结构式问卷调查方法，对北京328例和广州271例患者的社会经济状况、治疗利用和费用以及因病误工天数进行回顾性分析。住院费用分别从北京市和广州市社会保险信息系统的两家医院数据库中提取。通过患者报告的门诊就诊率和平均每次就诊费用来衡量患者的门诊费用，而通过不同类型医院的年住院率和平均费用来计算住院费用。也报告了自我药疗和直接非医疗费用。结果：慢性乙型肝炎、代偿期肝硬化、失代偿期肝硬化和肝癌患者的年成本分别为1636美元、2722美元、4611美元和6615美元，广州分别为1452美元、2065美元、4290美元和6054美元。本研究证实，CHB相关疾病给中国城市地区的患者、家庭和社会带来了巨大的经济负担。该研究表明，与疾病进展相关的医疗保健费用不断增加，并提供了有关不同疾病状态的治疗费用和工作损失的有用信息，这些信息可进一步用于成本效益评估。
Objective: To estimate the total annual cost due to Chronic Hepatitis B (CHB)-related diseases imposed on each patient and his/her family in Beijing and Guangzhou, China.Methods: Economic burden of CHB-related diseases (CHB, compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma) were examined. A retrospective cohort of 328 patients in Beijing and 271 in Guangzhou were identified to obtain their socioeconomic status, utilization and costs of treatment, and work loss days due to illness with a structured questionnaire. Costs of hospitalization were extracted from databases of two hospitals in Beijing and Guangzhou Social Insurance Information System, respectively. The outpatient expenditure per patient was measured through the rate of outpatient visits and average cost per visit reported by the patients, while the inpatient cost was calculated through annual rate of hospitalization and average expenditure for different types of hospitals. Self medication and direct nonmedical cost were also reported. The Human Capital Approach was employed to measure the work loss cost.Results: The total annual cost per patient for CHB, compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma were US$1636, US$2722, US$4611, and US$6615 in Beijing, and US$1452, US$2065, US$4290 and US$6054 in Guangzhou, respectively.Conclusion: This Study confirms that CHB-related diseases impose a substantial economic burden on patients, families, and the society in China urban areas. The study demonstrates increasing health-care costs related to disease progression and provides useful information on cost of treatment and work loss for different disease states, which can be further utilized in cost-effectiveness evaluation.